Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Vanguard Total World Stock Index Fund ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Vanguard Total World Stock Index Fund ETF trades at $157.18 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 104.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Vanguard Total World Stock Index Fund ETF for 54 Days on average.
| MRVI | VT | |
|---|---|---|
Market Cap | $972.90M | $101.70B |
Volume | 4,325,710 | 7,186,242 |
Sector | Health | Broad Market / Factor |
52-Week High | $9.00 | $162.39 |
52-Week Low | $2.83 | $134.19 |
Typical Hold Time | 0 Days | 54 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Vanguard Total World Stock ETF (VT) trades at $159.76, showing modest daily gains of 0.16% with neutral technical indicators. The ETF maintains broad global diversification across 9,773 stocks with a low 0.06% expense ratio. Recent news highlights VT's strong five-year performance compared to international-focused peers, though some competitors offer lower fees. Technical analysis shows the ETF trading near pivot point resistance at $160 with support at $159.
VT provides comprehensive global equity exposure but faces fee competition from alternatives like SPDW. The ETF's broad diversification minimizes country-specific risks while capturing global growth. Key risks include expense ratio pressure and emerging market volatility. Analyst sentiment remains positive for long-term investors seeking one-stop global diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
